Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
The immune system consists of two parts: innate immunity and adaptive immunity. T cells and B cells in the adaptive immune system are two major players to mount an antigen-specific defense and offer long-term protection. However, due to the immune tolerance and immunodominance mechanisms, some T cells and B cells can recognize the antigens but couldn’t develop effective immune responses.
My research focus is using synthetic biomaterials to engineer the innate immune system and unlock the non-responsive adaptive immune repertoire for new cancer immunotherapies and infectious disease vaccines. In this seminar, two examples illustrating my research work will be described. In the first example, I develop a toll-like receptor 7 agonist-based nanoparticle (TLR7-NP) adjuvant to alter germinal center (GC) signaling and induce high levels of cross-reactive antibody responses to multiple heterologous viral variants of influenza and SARS-CoV-2.
The second example is to design a nanoparticle platform to reverse the anergy of tumor infiltrating self-specific CD8+ T cells for creating a new and effective immunotherapeutic strategy for treating broad cancer patients.
